Last mentioned: Mar 24, 2026
Data Collection Completion
Expected completion of clinical data collection for burn applications.
Regulatory Submission
Target window for potential FDA submission for DeepView System clearance.
Clinical Study Expansion
Commencement of expanded clinical validation studies for burn care.
BARDA Award Announced
Spectral AI receives $31.7 million to accelerate DeepView development.
BARDA Award Announced
Spectral AI receives $31.7M in additional funding for DeepView development.
Clinical Validation Phase
Planned acceleration of clinical trials and R&D activities funded by the award.
Spectral AI, Inc. closed fiscal year 2025 with $19.7 million in research and development revenue and a robust $15.4 million cash balance. The company is now transitioning toward a commercial model, supported by newly introduced revenue guidance for the 2026 fiscal year.
Spectral AI has been awarded $31.7 million in additional funding from the Biomedical Advanced Research and Development Authority (BARDA) to accelerate the development and clinical validation of its DeepView® System. This non-dilutive capital will support the company's efforts to bring AI-driven diagnostic precision to burn and wound care, particularly for mass casualty scenarios.
Spectral AI has been awarded $31.7 million from the Biomedical Advanced Research and Development Authority (BARDA) to accelerate the development and clinical validation of its DeepView® System. This non-dilutive funding supports the integration of AI-driven predictive analytics into burn and wound care, aiming to improve triage and treatment outcomes in both clinical and emergency response settings.
Spectral AI (NASDAQ: MDAI) has been awarded $31.7 million in non-dilutive funding from BARDA to accelerate the development and clinical validation of its DeepView® System. This AI-powered diagnostic platform aims to provide rapid, accurate assessments of burn wounds and diabetic foot ulcers, potentially transforming emergency and routine wound care.